Ilaris (Canakinumab/PF) Patent Expiration, LOE Window & CMS Spending

Ilaris (Canakinumab/PF) by Novartis: Off-Patent Genericized (AB Competition), 0 AB generics, $218.5M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNovartis
FDA Application & PathwayReconciled (UNLINKED)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$218.5M
2024 Medicare Part D Spend$55.7M
2024 Medicaid Spend$162.7M
Reported Wholesale Price Change (CA SB 17)4 WAC filings (max 25.9% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.